Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PentaHibe
- Development stage
- Preclinical
- Lead developer
- Pharmacosmos
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
PentaHibe is a trademarked pharmaceutical candidate developed by Pharmacosmos, a company specializing in carbohydrate chemistry and intravenous iron therapies. While specific clinical details and molecular structures have not been publicly disclosed, the trademark is registered for the treatment of iron deficiency and iron deficiency anemia. Given Pharmacosmos's established portfolio, which includes products like ferric derisomaltose (Monoferric) and iron dextran (CosmoFer), PentaHibe is likely a next-generation iron-carbohydrate complex designed for intravenous iron replacement. The drug was previously associated with AMAG Pharmaceuticals through their commercial partnership for iron deficiency treatments in the United States.
- Brand names
- PentaHibe
Beyond the preview
Go deeper on PentaHibe.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PentaHibe.